For research use only. Not for therapeutic Use.
Pimicotinib (ABSK021)(CAT: I040786) is an orally active, selective inhibitor of colony-stimulating factor 1 receptor (CSF-1R), developed by Abbisko Therapeutics. It modulates macrophage activity by blocking CSF-1R signaling, showing strong potential in treating macrophage-driven diseases. Pimicotinib has received Breakthrough Therapy Designation from both the FDA and China’s NMPA for treating tenosynovial giant cell tumor (TGCT) in patients ineligible for surgery. Currently in Phase III clinical trials, it is also being investigated for chronic graft-versus-host disease (cGVHD). Pimicotinib represents a promising therapeutic candidate in immuno-oncology and inflammatory disease research, offering a targeted, non-surgical treatment strategy for CSF-1R–related pathologies.
| CAS Number | 2253123-16-7 |
| Synonyms | 3,3-dimethyl-N-[6-methyl-5-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxypyridin-2-yl]-2-oxopyrrolidine-1-carboxamide |
| Molecular Formula | C22H24N6O3 |
| Purity | ≥95% |
| IUPAC Name | 3,3-dimethyl-N-[6-methyl-5-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxypyridin-2-yl]-2-oxopyrrolidine-1-carboxamide |
| InChI | InChI=1S/C22H24N6O3/c1-14-18(31-16-7-9-23-17(11-16)15-12-24-27(4)13-15)5-6-19(25-14)26-21(30)28-10-8-22(2,3)20(28)29/h5-7,9,11-13H,8,10H2,1-4H3,(H,25,26,30) |
| InChIKey | NXFPMDWYDKHFMM-UHFFFAOYSA-N |
| SMILES | CC1=C(C=CC(=N1)NC(=O)N2CCC(C2=O)(C)C)OC3=CC(=NC=C3)C4=CN(N=C4)C |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
